Silence Therapeutics (SLN) Assets Average (2022 - 2026)

Silence Therapeutics has disclosed Assets Average across 5 years of filings, most recently posting $123.3 million for Q1 2026.

• Assets Average for Q1 2026 came in at $123.3 million, down 36.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.3 million (down 36.44% YoY), and the FY2025 annual result was $167.0 million, up 3.72% from the prior year.
• Assets Average came in at $123.3 million for Q1 2026 at Silence Therapeutics, down from $139.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $457.1 million in Q4 2023 to a low of $123.3 million in Q1 2026.
• The 5-year median for Assets Average is $179.5 million (2024), against an average of $246.4 million.
• Across the five-year window, Assets Average advanced 17.06% in 2023 and sank 65.1% in 2024, its largest moves.
• Silence Therapeutics' Assets Average stood at $390.5 million in 2022, then rose by 17.06% to $457.1 million in 2023, then tumbled by 65.1% to $159.5 million in 2024, then declined by 12.8% to $139.1 million in 2025, then fell by 11.38% to $123.3 million in 2026.
• The last three Assets Average figures came in at $123.3 million (Q1 2026), $139.1 million (Q4 2025), and $156.0 million (Q3 2025), per Business Quant data.